Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems. It develops kt-2000 series, which are patented class of oral, small molecule PARP inhibitors with established in vitro and in vivo proof of concept; kt-3000 series drug candidates, which are bi-functional targeted small molecules designed to inhibit both PARP and histone deacetylase; and kt-4000 series, which are small molecules engineered to induce targeted DNA damage in tumor cells. The company is also involved in the development of kt-5000 series of brain-penetrant dual ATR–mTOR inhibitor drug candidates. It has a strategic collaboration with Variational AI Inc. to develop AI-generated ATR inhibitor compounds; and a non-binding Letter of Intent to form a joint venture to co-develop AI-discovered small-molecule oncology therapies. The company was formerly known as Vincero Capital Corp. Rakovina Therapeutics Inc. is headquartered in Vancouver, Canada.